A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Clinical trial NCT05798819 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05798819
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-01
- Primary completion
- 2025-05-01
- Enrollment
- 424
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.